Search Within

Hematology-Oncology Fellows

Formats
  1. Meeting Abstract (636)
  2. Journal Article (509)
  3. Review (142)
  4. Editorial (64)
  5. Research Letter (50)
  6. Correspondence (15)
  7. Guidelines (6)
  8. Book Section (3)
  9. Conference Paper (2)
  10. Miscellaneous (2)
Groups
  1. Department of Medicine (1165)
  2. Graduate Medical Education (1122)
  3. GME, Medicine (1098)
  4. Hematologic Malignancies, Division of (752)
  5. Weinberg Fellows (660)
  6. Solid Tumor Oncology Division (617)

More Groups

People
  1. Jan Bewersdorf (102)
  2. Maria Palomba (94)
  3. Zachary Epstein-Peterson (94)
  4. Gunjan Shah (93)
  5. Gilles Salles (89)
  6. Michael Scordo (87)

More People

Years
  1. 2025 (165)
  2. 2024 (357)
  3. 2023 (296)
  4. 2022 (222)
  5. 2021 (159)
  6. 2020 (114)

More Years

Publications
  1. Blood (288)
  2. Journal of Clinical Oncology (219)
  3. Clinical Cancer Research (38)
  4. Annals of Oncology (35)
  5. Cancer Research (35)
  6. Journal of Thoracic Oncology (31)

More Publications

Publishers
  1. American Society of Hematology (323)
  2. American Society of Clinical Oncology (251)
  3. Elsevier Inc. (143)
  4. Nature Publishing Group (107)
  5. American Association for Cancer Research (104)
  6. Oxford University Press (61)

More Publishers

Results (1429)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • International Working Group (IWG) response criteria and association with overall survival in patients with myelodysplastic syndromes treated with hypomethylating agents - A systematic review and meta-analysis
    Meeting Abstract

    Bewersdorf, J. P.; Grimshaw, A.; Platzbecker, U.; Fenaux, P.; Sekeres, M. A.; Zeidan, A. M.; Stahl, M. F.
    Blood (2022)

    Fulltext@MSK | Save
  • Outcomes of therapies and resistance mutations following non-covalent Bruton's Tyrosine Kinase inhibitor treatment for patients with chronic lymphocytic leukemia and Richter Transformation
    Meeting Abstract

    Thompson, M. C.; Coombs, C. C.; Roeker, L. E.; Jensen, J. L.; Shah, N. N.; Luo, T.; Patel, K.; Bailey, N.; Fakhri, B.; Eyre, T. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Characterization of a large cohort of patients with nodal marginal zone lymphoma shows prolonged survival, time-to-treatment, and time-to-transformation
    Meeting Abstract

    Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A multi-center phase Ib trial of the histone deactylase inhibitor (HDACi) entinostat in combination with anti-pd1 antibody pembrolizumab in patients with refractory/relapsed myelodysplastic syndromes (RR-MDS) or oligoblastic acute myeloid leukemia (RR-AML) after hypomethylating agent (HMA) failure
    Meeting Abstract

    Bewersdorf, J. P.; Shallis, R. M.; Sharon, E.; Caldwell, A.; Wei, W.; Yacoub, A.; Madanat, Y. F.; Zeidner, J. F.; Altman, J. K.; Odenike, O.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Adolescent and young adults with ALL who complete therapy on DFCI Consortium ALL trials have excellent long-term overall survival
    Meeting Abstract

    Valtis, Y. K.; Flamand, Y.; Shimony, S.; Place, A. E.; Silverman, L. B.; Vrooman, L. M.; Brunner, A. M.; Sallan, S. E.; Wadleigh, M.; Stone, R. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Impact of allelic state on overall survival in TP53-mutant acute myeloid leukemia (AML) and higher risk myelodysplastic syndromes (HR-MDS)
    Meeting Abstract

    Bewersdorf, J. P.; Hasle, V.; Shallis, R. M.; Thompson, E. G.; de Menezes, D. L.; Rose, S.; Boss, I. W.; Halene, S.; Haferlach, T.; Fox, B.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • A phase II clinical trial of E7820 for patients with relapsed/refractory myeloid malignancies with mutations in splicing factor genes
    Meeting Abstract

    Bewersdorf, J. P.; Stahl, M. F.; Taylor, J.; Chandhok, N. S.; Watts, J.; Derkach, A.; Wysocki, M.; Kostantakis, V.; Lu, S. X.; Bourcier, J.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Phase I study of ruxolitinib in combination with abemaciclib for patients with primary or post-polycythemia vera/ essential thrombocythemia myelofibrosis
    Meeting Abstract

    Bewersdorf, J. P.; Verstovsek, S.; Derkach, A.; Masarova, L.; Pemmaraju, N.; Stein, E.; Mauro, M.; Rampal, R. K.; Bose, P.
    Blood (2022)

    Fulltext@MSK | Save